Abstract: Compounds of formula I or pharmaceutically acceptable salts thereof: wherein R1, R2, R3 and R4 are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.

Abstract: The present invention relates to compounds of formula (I) [Chemical formula should be inserted here. Please see paper copy] as well as pharmaceutically acceptable salts and pharmaceutical compositions including the compounds are prepared or thereof: wherein, A1, A2, R1, R2, R3, R4, and R5 and n are as defined in the specification. The compounds of formula (I) are useful in therapy.

Abstract: A vibratory system for asbestos treatment includes a trough with a heat-resistant liner, an opening, and a discharge end. The system also includes a transportation sub-system including a frame that may be coupled to the trough, as well as a vibration generator and resilient members coupled to the frame. Further, the system includes a heating sub-system including a furnace that may be disposed across the opening. A method for asbestos treatment includes disposing the asbestos in the trough, disposing the furnace across the opening, heating the asbestos in the trough to render the asbestos inert, vibrating the trough to move the inert asbestos along the trough to the discharge end, and collecting the inert asbestos from the trough.

Abstract: Compounds of Formulae I, or pharmaceutically acceptable salts thereof: wherein R1, R2 and Y are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.

Abstract: A vehicular steering angle estimating apparatus including wheel rotational speed sensors for detecting rotational speeds of left and right wheels of a vehicle, provided with a steering angle estimating portion for estimating and outputting a estimated steering angle 1 from the wheel rotational speeds detected by the wheel rotational speed sensors, and a estimated steering angle outputting portion for outputting a estimated steering angle 2 on the basis of the estimated steering angle 1 and an SAT detected value or an SAT estimated value.

Abstract: Compounds of formula I or pharmaceutically acceptable salts thereof: wherein R1, R2, R3, R4 and n are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.

Abstract: There is provided an absolute steering angle detecting device for detecting an absolute steering angle of a steering control device of a vehicle, including a sensor wheel 18c adapted to rotate by linking with rotation of the steering control device, a magnetism detector 18g having a bridge circuit made up of a GMR element, magnetized portions 18d, 18e provided to surround the magnetism detector 18g, and a steering angle operation module 26 which calculates an absolute steering angle based a detection signal outputted from the magnetism detector 18g, wherein either the magnetism detector 18g or the magnetized portions 18d, 18e is mounted on the sensor wheel 18c, while the other is mounted on a fixed portion, and the magnetism detector 18g outputs a detection signal which completes a single period when the steering control device completes a single rotation.

Abstract: The present invention provides an electric power steering apparatus having: a motor that applies a steering assist power to a steering mechanism; a torque command value calculating part that calculates a torque command value based on a steering torque generated in a steering shaft and a vehicle speed; and a current command value calculating part that calculates a current command value of the motor based on the torque command value, and the motor is controlled based on the current command value, and the electric power steering apparatus further has: a yaw rate detecting part that detects or estimates a yaw rate of a vehicle; a target yaw rate calculating part that calculates a target yaw rate based on the vehicle speed and a steering angle; and a correcting part that calculates an amount of correction based on the yaw rate and the target yaw rate to correct the current command value.

Abstract: An electromechanical/solid-state AC relay has an electromechanical winding coil that moves an armature to force mechanical contacts to open or close. Electrical arcing across the mechanical contacts that occur as the contacts are opening or closing can damage and severely reduce the lifetime of the relay. Contact arcing is prevented by pulsing a triac on for a short period of time just before and after the mechanical contacts make or break contact. The triac limits the voltage difference across the mechanical contacts to less than one volt to prevent arcing. The triac is turned off after the mechanical contacts finish moving, reducing the heating and average power through the triac. A zero-sampling circuit that detects when the AC input voltage switches across 0 volts and activates a control integrated circuit to switch on the triac during zero-crossings to minimize power surges.

Abstract: Compounds of formula I or pharmaceutically acceptable salts thereof: wherein R1, R2, R3 and R4 are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.

Abstract: A control device for an electric power steering apparatus is adapted to calculate a current command value of a motor for applying a steering assist force to a steering mechanism in accordance with a steering torque and a vehicle speed so that the motor is driven and controlled under a feedback control. The control device includes an SAT estimating part for inputting an angular velocity and an angular acceleration of the motor, the steering torque and the current command value to estimate an SAT and a correcting part for determining a traveling state of a vehicle in accordance with the SAT value estimated in the SAT estimating part, the steering torque and a steering angle to correct the current command value depending on the traveling state.

Abstract: Compounds of formula I or pharmaceutically acceptable salts thereof: wherein R1, R2, R3, R4, n and A are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.

Abstract: Compounds of formula I or pharmaceutically acceptable salts thereof: wherein R1, R2, R3, R4, m and n are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.

Abstract: Methods for the racemization of an enantiomer of a 2,3-benzodiazepine molecule into the corresponding racemic mixture under either basic or acidic conditions are described. Furthermore, the invention relates to the conversion of an enantiomer of tofisopam or its metabolites to the corresponding opposite enantiomer.

Abstract: A process for the preparation of 14-alkoxyindolomorphinans and 14-alkoxybenzofuranomorphinans is disclosed. The process facilitates the preparation of a large variety of 14-alkoxy substituted indolomorphinans and benzofuranomorphinans in which a 3-hydroxy substituent is present.

Abstract: This invention provides a compound having the formula R.sup.1 -Y.sup.1 --CHZ.sup.1 -CH(NY.sup.2 Y.sup.3)--CH.sub.2 -Z.sup.2, wherein: R.sup.1 is a straight-chained alkyl, alkenyl or alkynyl group having from 8 to 19 carbon atoms in the aliphatic chain; Y.sup.1 is --CH.dbd.CH--, --C.tbd.C-- or --CH(OH)CH(OH)--; Z.sup.1 is OH or a conversion-inhibiting group; Z.sup.2 is a conversion-inhibiting group; Y.sup.2 is H, a phenyl group, an alkyl-substituted phenyl group having from 1 to about 6 carbons in the alkyl chain, or an alkyl chain having from 1 to 6 carbons; Y.sup.3 is H or a group having the formula --C(O)R.sup.2 or --S(O).sub.2 R.sup.2 ; R.sup.2 is a straight-chained alkyl, alkenyl or alkynyl group having from 1 to 23 carbon atoms in the chain; and when Z.sup.2 is an amino, R.sup.2 is an aliphatic chain having from 1 to 9 or from 19 to 23 carbon atoms in the aliphatic chain.

Abstract: This invention provides a compound having the formula R.sup.1 --Y.sup.1 --CHZ.sup.1 --CH(NY.sup.2 Y.sup.3)--CH.sub.2 --Z.sup.2, wherein: R.sup.1 is a straight-chained alkyl, alkenyl or alkynyl group having from 8 to 19 carbon atoms in the aliphatic chain; Y.sup.1 is --CH.dbd.CH--, --C.tbd.C-- or --CH(OH)CH(OH)--; Z.sup.1 is OH or a conversion-inhibiting group; Z.sup.2 is a conversion-inhibiting group; Y.sup.2 is H, a phenyl group, an alkyl-substituted phenyl group having from 1 to about 6 carbons in the alkyl chain, or an alkyl chain having from 1 to 6 carbons; Y.sup.3 is H or a group having the formula --C(O)R.sup.2 or --S(O).sub.2 R.sup.2 ; R.sup.2 is a straight-chained alkyl, alkenyl or alkynyl group having from 1 to 23 carbon atoms in the chain; and when Z.sup.2 is an amino, R.sup.2 is an aliphatic chain having from 1 to 9 or from 19 to 23 carbon atoms in the aliphatic chain.

Abstract: This invention provides a compound having the formula R.sup.1 --Y.sup.1 --CHZ.sup.1 --CH(NY.sup.2 Y.sup.3)--CH.sub.2 --Z.sup.2, wherein: R.sup.1 is a straight-chained alkyl, alkenyl or alkynyl group having from 8 to 19 carbon atoms in the aliphatic chain; Y.sup.1 is --CH.dbd.CH--, --C.tbd.C-- or --CH(OH)CH(OH)--; Z.sup.1 is OH or a conversion-inhibiting group; Z.sup.2 is a conversion-inhibiting group; Y.sup.2 is H, a phenyl group, an alkyl-substituted phenyl group having from 1 to about 6 carbons in the alkyl chain, or an alkyl chain having from 1 to 6 carbons; Y.sup.3 is H or a group having the formula --C(O)R.sup.2 or --S(O).sub.2 R.sup.2 ; R.sup.2 is a straight-chained alkyl, alkenyl or alkynyl group having from 1 to 23 carbon atoms in the chain; and when Z.sup.2 is an amino, R.sup.2 is an aliphatic chain having from 1 to 9 or from 19 to 23 carbon atoms in the aliphatic chain.

Abstract: A method for promoting weight control by treating a subject with a therapeutic amount of one of the .DELTA.5-androstenes listed below to stimulate weight control without affecting appetite or inducing the synthesis of sex hormones..DELTA.5-Androstenes providing the desired biological activities include:.DELTA.5-Androstene-3.beta.,7.alpha.-diol-17-one (1).DELTA.5-Androstene-3.beta.-ol-7,17-dione (2).DELTA.5-Androstene-3.beta.,7.alpha.,17.beta.-triol (3).DELTA.5-Androstene-3.beta.,17.beta.-diol-7-one (4).DELTA.5-Androstene-3.beta.-acetoxy-7,16,17-trione (5).DELTA.5-Androstene-3.beta.,16.alpha.-dihydroxy-7,17-dione (6).DELTA.5-Androstene-3.beta.-propionoxy-16.beta.-acetoxy-7,17-dione (7).DELTA.5-Androstene-3.beta.,7.alpha.,17.beta.-triol-16-one (8).DELTA.5-Androstene-3.beta.,17.beta.-diol-7,16-dione (9).DELTA.5-Androstene-3.beta.,16.alpha.,17.beta.-triol-7-one (10)and derivatives thereof wherein one or more of the hydroxyl or keto substituents is a group convertible thereto by hydrolysis.

Abstract: A method for promoting weight control by treating a subject with a therapeutic amount of one of the .DELTA.5-androstenes listed below to stimulate weight control without affecting appetite or inducing the synthesis of sex hormones. .DELTA.5-Androstenes providing the desired biological activities include:.DELTA.5-Androstene-3.beta.,7.alpha.-diol-17-one.DELTA.5-Androstene-3.beta.-ol-7,17-dione.DELTA.5-Androstene-3.beta.,7.alpha.,17.beta.-triol.DELTA.5-Androstene-3.beta.,17.beta.-diol-7-one.DELTA.5-Androstene-3.beta.-acetoxy-7,16,17-trione.DELTA.5-Androstene-3.beta.,16.alpha.-dihydroxy-7,17-dione.DELTA.5-Androstene-3.alpha.-propionoxy-16.beta.-acetoxy-7,17-dione.DELTA.5-Androstene-3.beta.,7.alpha.,17.beta.-triol-16-one.DELTA.5-Androstene-3.beta.,17.beta.-diol-7,16-dione.DELTA.5-Androstene-3.beta.,16.alpha.,17.beta.-triol-7-one.